Skip to content
Catalyst

beta-cryptoxanthinFinding

Beta-cryptoxanthin decreases alanine aminotransferase

lowersModerate evidenceFinding

01 · The sentence it was drawn from

“In addition, patients in the β-cryptoxanthin group only showed a greater 12-week reduction in serum level of ALT, compared to those in the control group (for ALT: mean difference − 9.6 IU/L; p = 0.005).”
Quoted verbatim from A hypocaloric high-protein diet supplemented with β-cryptoxanthin improves non-alcoholic fatty liver disease: a randomized controlled trial.
This finding among the 73 findings on its endpoint

beta-cryptoxanthin

Alanine aminotransferase

lowers

Effect as reported

−9.6mean difference

Who
Iranian overweight/obese adults with moderate-to-severe non-alcoholic fatty liver disease; the same 500 kcal/day-deficit normal-protein diet in both arms; intention-to-treat, multivariable-adjusted ANCOVA contrast against the control arm
Dose studied
6 mg/day β-cryptoxanthin, one 600 mg capsule (powder 1% β-cryptoxanthin, 99% starch) daily after dinner, 12 weeks

Moderate evidencePMID 33081717 · 2020

02 · The study

Study
RCT
Duration
3 months

Evidence, by strength

  • strong
  • moderatethis finding
  • limited
  • very limited
  • insufficient

04 · To cite this finding

This address does not change

https://catalystproject.ai/e/01M7GECAW2D22RW3DVAC91XGKC